Collaboration and License Agreements - Additional Information (Details) - USD ($) $ in Thousands		1 Months Ended		3 Months Ended		9 Months Ended
	May 08, 2023	Jul. 31, 2023	Mar. 31, 2020	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Collaboration And License Agreements [Line Items]
Collaboration and license revenue				$ 3,887	$ 3,363	$ 13,838	$ 10,440
Long-term deferred revenue				7,758		7,758
Novartis
Collaboration And License Agreements [Line Items]
License agreement date			Mar. 31, 2020
Collaboration and license revenue						5,800	$ 10,400
Amgen Inc. | Amgen Agreement
Collaboration And License Agreements [Line Items]
License agreement date	May 08, 2023
Upfront payment receivable	$ 30,000
Upfront payment received		$ 30,000
Upfront payment	$ 500,000
Expects research term	3 years
Collaboration and license revenue				3,900		7,000
Deferred revenue				23,000		23,000
Long-term deferred revenue				$ 7,800		$ 7,800